We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA (MESA-LUNG)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by Columbia University.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00843271
First Posted: February 13, 2009
Last Update Posted: January 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Columbia University
February 12, 2009
February 13, 2009
January 16, 2012
October 2004
November 2012   (Final data collection date for primary outcome measure)
Lung Function [ Time Frame: 2004-2011 ]
Same as current
Complete list of historical versions of study NCT00843271 on ClinicalTrials.gov Archive Site
Lung Density [ Time Frame: 2000-2011 ]
Same as current
Not Provided
Not Provided
 
Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA
Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)
The purpose of MESA-Lung is to assess the role of endothelial dysfunction and genetic susceptibility in subclinical COPD.

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD that might lead to the development of better therapies for COPD.

MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
MESA cohort
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Emphysema
  • Endothelial Dysfunction
Not Provided
MESA Lung
MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
4359
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • A random sample of MESA participants active at Exam 3 and/or 4.

Exclusion Criteria:

  • MESA participants without MESA Exam 3 or 4 measurements.
  • MESA participants without FMD measurements in Exam 1.
  • MESA participants who have not consented to genetic testing.
Sexes Eligible for Study: All
45 Years to 84 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00843271
AAAA7791
R01HL077612 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Columbia University
Columbia University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: R. Graham Barr, M.D., Dr.PH. Columbia University
Columbia University
January 2012